FDA panel votes in favor of antipsychotic asenapine
스크롤 이동 상태바
FDA panel votes in favor of antipsychotic asenapine
기자명
메디칼라이터팀
입력 2009.08.03 00:00
수정 2009.08.03 08:56
댓글 0
An advisory panel to the FDA voted for the approval of Schering-Plough"s asenapine in addition voted 12-0 in favor of its use in treating manic or mixed episodes of bipolar disorder. The new antipsychotic drug will be marketed as Saphris. The panel found that its benefits outweighed side-effects in adults with schizophrenia although these medications have caused concern about weight gain. According to Schering-Plough studies done by the company indicated that fewer patients taking asenapine experienced higher levels cholesterol or increased tendency to gain weight. Some of the panel did suggest that a 10 milligram dose might be too much in some patients with bipolar disorder and proper dosage is important.